Meeting
2019 ASCO Annual Meeting
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
Authors
Derek B. Grose
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Derek B. Grose , Colin J McKay , Susie Cooke , Janet Shirley Graham , Fraser Duthie , Nigel Jamieson , Reena Ravikumar , Aileen Duffton , David McIntosh , Rebecca Goody , Ganesh Radhakrishna , Maria A Hawkins , Dave Colville , Christine Willshire , Jon Stobo , James Paul , Sarah Bradley , Judith Dixon-Hughes , Andrew Victor Biankin , David Kuang-Fu Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
ISRCTN34129115
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4166)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4166
Abstract #
TPS4166
Poster Bd #
258b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
First Author: Derek B. Grose
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2018 ASCO Annual Meeting
A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.
First Author: Manisha Palta